Abstract:To investigate the antitumor effect of iridium complexes, three iridium (III) complexes [Ir(ppy)(2)(dcdppz)]PF6(ppy = 2-phenylpyridine, dcdppz = 11,12-dichlorodipyrido [3,2-a:2',3'-c]phenazine) (Ir1), [Ir(bzq)(2)(dcdppz)] PF6 (bzq = benzo[h]quinoline) (Ir2) and [Ir(piq)(2)(dcdppz)]PF6 (piq = 1-phenylisoquinoline) (Ir3) were synthesized and characterized. Geometry optimization, molecular dynamics simulation and docking studies have been performed to further explore the antitumor mechanism. The cytotoxicity of Ir1-3 toward cancer cells was studied by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MIT) method. The localization of complexes Ir1-3 in the mitochondria, intracellular accumulation of reactive oxygen species (ROS) levels, the changes of mitochondrial membrane potential and morphological changes in apoptosis were investigated. Flow cytometry was applied to quantify fluorescence intensity and determine cell cycle distribution. Western blotting was used to detect the expression of apoptosis-related proteins. The anti-tumor effect of Ir1 in vivo was evaluated. The results showed that Ir1-3 had high cytotoxicity to most tumor cells, especially to SGC-7901 cells with a low IC50 value. Ir1-3 can increase the intracellular ROS levels, reduce the mitochondrial membrane potential. Additionally, the complexes induce an increase of apoptosis-related protein expression, enhance the percentage of apoptosis. The complexes inhibit the cell proliferation at G0/G1 phase. The results obtained from antitumor in vivo indicate that Irl can significantly inhibit the growth of tumors with an inhibitory rate of 54.08%. The docking studies show that complexes Ir1-3 interact with DNA through minor-groove intercalation, which increases the distance of DNA base pairs, leading to a change of DNA helix structure. These experimental and theoretical findings indicate that complexes Ir1-3 can induce apoptosis in SGC-7901 cells through the mitochondrial dysfunction and DNA damage pathways, and then exerting anti-tumor activity in vitro and vivo.

Identification of an Iridium(III)-Based Inhibitor of Tumor Necrosis Factor-α

Design, synthesis, and antitumor mechanism investigation of iridium(III) complexes conjugated with ibuprofen

Synthesis and Antineoplastic Applications of TPE Appended Organometallic Iridium(III) Complexes.

Synthesis and in Vitro Antitumor Activity of Novel Iridium(iii) Complexes with Enantiopure C2-symmetrical Vicinal Diamine Ligands

A rhodium(III)-based inhibitor of autotaxin with antiproliferative activity

Iridium(III) complexes conjugated with naproxen exhibit potent anti-tumor activities by inducing mitochondrial damage, modulating inflammation, and enhancing immunity

Anticancer effect evaluation in vitro and in vivo of iridium(III) polypyridyl complexes targeting DNA and mitochondria

Mitochondria-targeted Cyclometalated Iridium-Β-carboline Complexes As Potent Non-Small Cell Lung Cancer Therapeutic Agents

Lysosome-Targeted Potent Half-Sandwich Iridium(Iii) Alpha-Diimine Antitumor Complexes

Inhibition of the Ras/Raf Interaction and Repression of Renal Cancer Xenografts in Vivo by an Enantiomeric Iridium(iii) Metal-Based Compound.

Design, Synthesis, and Evaluation of Dihydrobenzo[ cd ]indole-6-sulfonamide as TNF-α Inhibitors.

Rhodium(I) Complexes Containing the N^N^N-Chelating Ligand: Synthesis, Structure, and Biological Activity

Synthesis, Characterization and Biological Evaluation of Two Cyclometalated Iridium(iii) Complexes Containing a Glutathione S-transferase Inhibitor.

Synthesis, Subcellular Localization and Anticancer Mechanism Studies of Unsymmetrical Iridium(III) Complexes

Discovery of an Orally Active Small-Molecule Tumor Necrosis Factor-α Inhibitor

Activation of C-H bonds in nitrones leads to iridium hydrides with antitumor activity.

Novel iridium(III) iminopyridine complexes: synthetic, catalytic, and in vitro anticancer activity studies

Cyclometalated Iridium(iii) Complexes As Mitochondria-Targeted Anticancer Agents.

Theranostic Lysosomal Targeting Anticancer and Antimetastatic Agents: Half-Sandwich Iridium(III) Rhodamine Complexes

An Anti-Prostate Cancer Benzofuran-Conjugated Iridium(iii) Complex As a Dual Inhibitor of STAT3 and NF-κB

Rational discovery of novel type-III FTF antagonists to competitively suppress TIF-2 coactivation in liver cancer